Welcome to our dedicated page for Compass Pathways Plc news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways Plc stock.
Compass Pathways Plc (Nasdaq: CMPS) is advancing innovative mental health solutions through its COMP360 psilocybin therapy program. This page provides centralized access to official company announcements, clinical trial updates, and strategic partnership developments.
Investors and researchers will find timely updates on regulatory progress, including FDA Breakthrough Therapy designations and international clinical trials. All content is curated to support informed analysis of the company's progress in treatment-resistant depression and related mental health conditions.
Key focus areas include therapy development milestones, healthcare collaboration models, and intellectual property advancements. Resources are organized to help track the company's evidence-based approach to psychedelic-assisted therapies within rigorous clinical frameworks.
Bookmark this page for direct access to primary source materials about CMPS's work in mental health innovation. Visit regularly to stay current with developments in this pioneering sector of biotechnology.
Compass Pathways (NASDAQ: CMPS) reported its Q4 and full-year 2024 financial results, highlighting ongoing progress in its clinical trials. The company's Phase 3 COMP005 trial for treatment-resistant depression (TRD) remains on schedule, with top-line data expected in Q2 2025.
Financial results show a net loss of $155.1 million ($2.30 per share) for 2024, compared to $118.5 million in 2023. R&D expenses increased to $119.0 million from $87.5 million, while G&A expenses rose to $59.2 million from $49.4 million.
The company's cash position stood at $165.1 million as of December 31, 2024, with an additional $140.4 million net cash raised in Q1 2025. Full-year 2025 net cash used in operating activities is projected between $120-145 million, with funding sufficient through the planned COMP006 26-week data readout in H2 2026.
Compass Pathways (Nasdaq: CMPS), a mental health-focused biotechnology company, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. The company's management will deliver a presentation on March 3rd, 2025, at 1:10 pm ET.
Investors and interested parties can access a live audio webcast of the presentation through the 'Events' page in the Investors section of the Compass website. The webcast recording will remain available for 30 days after the event.
Compass Pathways (NASDAQ: CMPS), a biotechnology company focused on mental health innovation, has announced it will release its Q4 and full-year 2024 financial results on February 27th, 2025. The company will host a conference call at 8:00 AM ET (1:00 PM UK) on the same day to discuss results and provide updates on recent developments. Investors can access the call through pre-registration, and a live webcast will be available on the company's website. The webcast recording will remain accessible for 30 days in the Investors section.
Compass Pathways (Nasdaq: CMPS), a biotechnology company focused on mental health innovation, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will deliver a presentation on February 12th, 2025, at 8:40 am ET.
Interested parties can access a live audio webcast of the presentation through the 'Events' page in the Investors section of the Compass website. The webcast recording will remain available for 30 days after the event.
Compass Pathways (NASDAQ: CMPS) has appointed Steve Levine, M.D., as Chief Patient Officer in a newly created executive role. Dr. Levine, who has been with Compass since 2020 as Senior Vice President of Patient Access, will focus on embedding patient-centric strategies across the organization and ensuring treatments address unmet clinical care needs.
Dr. Levine is a board-certified psychiatrist with extensive experience in healthcare innovation and access. He previously founded Actify Neurotherapies, developing care delivery models for interventional psychiatry treatments. His academic background includes training at New York-Presbyterian Hospital/Weill Cornell Medical Center and Memorial Sloan Kettering Cancer Center. He currently serves as an adjunct professor at Rutgers Medical School.
Compass Pathways (NASDAQ: CMPS) has announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares (ADSs) and pre-funded warrants for up to 11,044,720 ADSs. Each ADS and pre-funded warrant includes an ADS Warrant with an exercise price of $5.796, representing a 40% premium to the last sale price.
The offering price is set at $4.275 per ADS and accompanying ADS Warrant, and $4.2649 per pre-funded warrant and ADS Warrant. The offering, led by Deep Track Capital, is expected to generate gross proceeds of approximately $150 million, potentially reaching $353 million if all ADS Warrants are exercised.
The proceeds will fund ongoing Phase 3 trials in treatment-resistant depression (COMP005 and COMP006), with data expected in Q2 2025 and H2 2026, respectively. Additionally, funds will accelerate a late-stage PTSD development program and support working capital needs.
Compass Pathways (Nasdaq: CMPS), a mental health-focused biotechnology company, announced its inclusion in the NASDAQ Biotechnology Index (NBI), effective December 23, 2024. The NBI tracks biotechnology and pharmaceutical companies listed on NASDAQ, using a modified market capitalization weighted methodology. Index membership requires companies to meet specific criteria including minimum market capitalization and average daily trading volume. The index undergoes annual reconstitution in December.
Compass Pathways (Nasdaq: CMPS), a mental health biotechnology company, has announced its participation in two major investor conferences this December. The company's executive management team will engage in fireside chats at the 7th Annual Evercore ISI HealthCONx Conference on December 3, 2024, at 10:25am ET, and the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 3:30pm ET. Live audio webcasts will be available for 30 days after the events.
Compass Pathways (NASDAQ: CMPS) announced key updates in its Q3 2024 financial results. The company reported a delay in its COMP360 phase 3 program, with top-line COMP005 data now expected in Q2 2025 and COMP006 data in H2 2026. The company is implementing a strategic reorganization, including a 30% workforce reduction and discontinuation of non-COMP360 preclinical efforts. Q3 2024 financial results showed a net loss of $38.5 million, with R&D expenses at $32.9 million and G&A expenses at $15.0 million. The company maintains a strong cash position of $207 million, expected to fund operations into 2026.
Compass Pathways (NASDAQ: CMPS), a mental health biotechnology company, announced it will release its third quarter 2024 financial results on October 31, 2024. The company will host a conference call at 8:00 am ET (12:00 pm UK) to discuss financial results and provide business updates. A live webcast will be available on the company's website and archived for 30 days.
FAQ
What is the current stock price of Compass Pathways Plc (CMPS)?
What is the market cap of Compass Pathways Plc (CMPS)?
